- Home
- Software Solutions
- Resources
- Corporate
Acorda Therapeutics, Inc
Acorda Therapeutics, Inc Clinical Studies by Phase of Development
Active Clinical Trials 
| Status | Indication | Name(s) | Phase | Trial Name | Identification |
|---|---|---|---|---|---|
| Active | Multiple Sclerosis | >Fampridine-SR | Phase_III | Study of Fampridine-SR Ta... | NCT00648908 |
| Active | Multiple Sclerosis | >Fampridine-SR | Phase_III | Open-Label Extension Stud... | NCT00654927 |
| Active | Multiple Sclerosis | >Fampridine-SR | Phase_III | Open-Label Extension Stud... | NCT00649792 |
| Active | Multiple Sclerosis | >Fampridine-PR | Phase_III | Open Label Extension Stud... | NCT01235221 |
| Active | Healthy | >Fampridine-PR | Phase_I | A Safety Study of Oral Fa... | NCT01215084 |
| Active | Heart Failure | >Glial growth factor 2 (neuregulin 1β3) >Glial growth factor 2/ Neuregulin 1β3 >Glial growth factor 2/ Neuregulin 1β3 >Glial Growth factor 2/ Neuregulin 1β3 >Glial Growth Factor 2/ Neuregulin 1β3 >Glial growth factor 2/ | Phase_I | Single Ascending Doses of... | NCT01258387 |
Completed Clinical Trials
| Status | Indication | Name(s) | Phase | Trial Name | Identification |
|---|---|---|---|---|---|
| Completed | Spinal Cord Injury Muscle Spasticity | >Fampridine-SR | Phase_III | Safety and Efficacy of Or... | NCT00041717 |
| Completed | Multiple Sclerosis | >Fampridine-SR (4-aminopyridine, 4-AP) | Phase_II | Safety and Efficacy Study... | NCT00053417 |
| Completed | Multiple Sclerosis | >Fampridine-SR (4-aminopyridine, 4-AP) | Phase_III | Study of Oral Fampridine-... | NCT00127530 |
| Completed | Multiple Sclerosis | >Fampridine-SR | Phase_III | Study of Fampridine-SR Ta... | NCT00483652 |